Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR‐Preserved Trial
Source : https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2420
Javed Butler , Corresponding Author Javed Butler Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, US Corresponding author. Javed Butler, MD MPH MBA. University of Mississippi Medical Center,...
Conclusion/Relevance: Our results reinforce the importance of early initiation of treatment in patients with HFpEF.
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34971904/
1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, 164 Worldcup-ro, Yeoungtong-gu, Suwon, 16499, Republic of Korea. 2 Department of Physiology, Ajou University School of Medicine, 164 Worldcup-ro,...
Conclusion: These findings suggest that the GEMI, EMPA, and GEMI EMPA treatments ameliorate hepatic steatosis, inflammation, oxidative stress, and fibrosis in CDAHFD-induced NAFLD mouse models.
Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2021.779282/full
Background: Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a major global public health burden and lacks effective risk stratification. We aimed to assess a multi-biomarker model...
Conclusions: Multiple circulating biomarkers coupled with an appropriate machine-learning method could effectively predict the risk of long-term mortality in patients with acute HFpEF. It is a promising strategy for improving risk stratification in HFpEF.
Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34939776/
doi: 10.2459/JCM.0000000000001267. Online ahead of print. 1 Preventive Cardiology and Preventive Medicine, Department of Cardiology. 2 Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz....
Conclusion: By evaluating the short-term effect of empagliflozin with a comprehensive biobanking program, the EmDia Study offers an opportunity to primarily assess the effects on diastolic function but also to examine effects on clinical and molecular cardiovascular traits.
Impact of Anemia and the Effect of Empagliflozin in HFrEF: findings from EMPEROR‐Reduced
Source : https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2409
Corresponding Author João Pedro Ferreira MD, PhD Université de Lorraine, Inserm, Centre d'Investigations Cliniques Plurithématique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France Cardiovascular...
Conclusions: Anemia was associated with poor outcomes. Empagliflozin reduced new onset anemia throughout the follow-up and improved heart failure and kidney outcomes irrespective of anemia status at baseline.